The possible link of CYP3A5 activity with blood pressure control, drug-metabolising activity of CYP3A5 and CKD progression have highlighted the potential role of CYP3A5 pharmacogenetics in optimising therapeutic management. Here, CYP3A5 is linked to chronic kidney disease.